GLP-1 & weight-loss drugs
Semaglutide and tirzepatide tracked half the femoral fractures of another diabetes drug
The worry about weight-loss drugs is that fast loss costs muscle and bone, which should show up as broken hips. Comparing 27,896 matched over-65s against a rival diabetes medicine, fractures and falls both ran lower over a year.
Sep 1, 2026
Sudden vision loss hit 3 more GLP-1 users per 10,000 over 18 months than two rival diabetes drugs
An Annals of Internal Medicine target trial emulation compared GLP-1 users against two other diabetes drug classes. Ischemic optic neuropathy was more common on GLP-1s, concentrated in men, over-50s and those with eye or heart disease.
Aug 28, 2026
An oral GLP-1 pill cut weight 9% in a phase 2 trial
A trial in Nature Communications tested a once-daily GLP-1 tablet in 235 Chinese adults with obesity. The top dose beat placebo by about 7 percentage points over 26 weeks, with the usual gut side effects.
Aug 4, 2026
GLP-1 drugs carried higher hair loss risk than two rivals
Comparing 12,004 people starting a GLP-1 drug against those starting other diabetes medicines, researchers found more diagnosed hair loss. The absolute risk stayed low.
Aug 2, 2026
GLP-1 drugs tracked with fewer fractures, but only with diabetes
A JAMA Network Open study of 133,606 matched patients found GLP-1 drugs linked to lower fracture risk in type 2 diabetes, and higher risk in people without it.
Jul 29, 2026
Mazdutide took off 16.7% of body weight in a phase 3 trial
A JAMA phase 3 trial of 461 Chinese adults with obesity found the dual glucagon and GLP-1 drug mazdutide cut body weight by 16.65% over 60 weeks against 1.50% on placebo.
Jul 29, 2026
Weight-loss drugs worked better with lifestyle, not without
A JAMA Pediatrics network meta-analysis of 42 trials in 3,835 adolescents found every obesity drug performed better paired with lifestyle treatment than on its own.
Jul 28, 2026
Stopping GLP-1 drugs tracked with more anxiety after
A Nature Metabolism study of Shanghai health records found GLP-1 drugs carried no extra psychiatric risk during treatment, but higher risk of depression and anxiety after people stopped.
Jul 28, 2026
Semaglutide led the field for antipsychotic weight gain
A JAMA Psychiatry network meta-analysis of 95 trials ranked 39 drugs for reversing antipsychotic weight gain, and semaglutide came out well ahead at nearly 11 kg.
Jul 27, 2026
Bariatric surgery cost less downstream than GLP-1 drugs
A JAMA Network Open study matched 2,721 pairs of Israeli patients over up to 12.5 years and found those on GLP-1 drugs ran up $109 more per month in other health costs than surgery patients.
Jul 27, 2026
Survodutide cleared liver fat in 84% of patients
A Nature Medicine phase 3 trial of 216 adults found survodutide cut liver fat by at least 30% in 84.2% of those treated, against 24.3% on placebo, alongside 12.2% weight loss.
Jul 27, 2026
Oral GLP-1 pill elecoglipron hit 10% weight loss in a trial
A Lancet phase 2 trial of 310 adults found the oral GLP-1 drug elecoglipron produced up to 10.5% weight loss in 26 weeks against 0.6% on placebo, with no injections and no food restrictions.
Jul 26, 2026
Apitegromab kept muscle on during tirzepatide weight loss
A Nature Medicine trial of 102 adults found adding the antibody apitegromab to tirzepatide cut lean-mass loss by 1.9 kilograms over 24 weeks, without slowing total weight loss.
Jul 25, 2026